

marized in Table I and show that either product can be made to predominate.⁶

TABLE I

Sensitizer ^a	Fluorescence maximum, m μ ^b	Total % conversion	Ratio III/II
Chlorin e ₆	670	85	1:4.5
Hematoporphyrin	630	80	1:4.5
Rose Bengal	580	88	1:1.2
Erythrosin B	578	71	1.6:1
Eosin Y	565	82	3.1:1
Riboflavin ^c	510	61	30:1

^a Photooxygenations were conducted in pyridine for 80 hr.

^b Measured in pyridine with an Aminco-Bowman Spectrofluorometer. ^c Owing to low solubility this run was in pyridine-methanol (4:1) for 110 hr. About the same product ratio was observed in pyridine alone but the total conversion was only 35%.

This finding has practical value for synthetic work and raises questions on the precise nature of the intermediates in sensitized oxygenations.⁷ Interestingly, there is a rough parallelism between the trend in product ratio and the trend in fluorescence emission maximum for the different sensitizers.

(6) Control experiments showed that both products are stable to the conditions of photooxygenation.

(7) An example of sensitizer control of product composition in a photochemical reaction not involving oxygen was reported recently [G. S. Hammond, N. J. Turro and A. Fischer, *J. Am. Chem. Soc.*, **83**, 4674 (1961)].

(8) This work was supported by a U. S. Public Health Service Grant (RG-9693), by a Grant-in-Aid from the Hynson, Westcott and Dunning Fund, and by the Alfred P. Sloan Foundation.

(9) Fellow of the Alfred P. Sloan Foundation.

DEPARTMENT OF CHEMISTRY⁸ ALEX NICKON⁹
THE JOHNS HOPKINS UNIVERSITY WILFORD L. MENDELSON
BALTIMORE 18, MARYLAND

RECEIVED APRIL 1, 1963

The Synthesis of a Biologically Active Pentadecapeptide Corresponding to an Altered Sequence in the Adrenocorticotropin (ACTH) Structure

Sir:

Since the synthesis¹ of a nonadecapeptide corresponding to the NH₂-terminal 19-amino acids in the 39-amino acid chain of ACTH structures, several investigators²⁻⁶ have reported the synthesis of various chain lengths. We wish to describe herein the synthesis of a pentadecapeptide with a structure consisting of the first ten NH₂-terminal residues linked with a sequence of positions 15 to 19 in ACTH structures; namely, L-seryl-L-tyrosyl-L-seryl-L-methionyl-L-glutamyl-L-histidyl-L-phenylalanyl-L-arginyl-L-tryptophyl-glycyl-L-lysyl-L-lysyl-L-arginyl-L-arginyl-L-proline. This synthetic product, designated as $\alpha^{(1-10)+(15-19)}$ -ACTH, was shown to have an ACTH potency of approximately 1 U.S.P. unit per mg., as estimated by *in vitro*⁷ and *in vivo*⁸ methods in the rat. The product was found to exhibit the full lipolytic potency of the natural⁹ α_5 -ACTH, when assayed¹⁰ *in vitro* with peri-

(1) C. H. Li, J. Meienhofer, E. Schnabel, D. Chung, T. B. Lo and J. Ramachandran, *J. Am. Chem. Soc.*, **82**, 5760 (1960); **83**, 4449 (1961).

(2) K. Hofmann, H. Yajima, N. Yanaihara, T. Y. Liu and S. Lande, *ibid.*, **83**, 488 (1961).

(3) H. Kappeler and R. Schwyzler, *Helv. Chim. Acta*, **44**, 1136 (1961).

(4) K. Hofmann, T. Y. Liu, H. Yajima, N. Yanaihara, C. Yanaihara and J. L. Hume, *J. Am. Chem. Soc.*, **84**, 1054 (1962).

(5) C. H. Li, D. Chung, J. Ramachandran and B. Gorup, *ibid.*, **84**, 2460 (1962).

(6) K. Hofmann, N. Yanaihara, S. Lande and H. Yajima, *ibid.*, **84**, 4470 (1962).

(7) M. Saffran and A. V. Schally, *Endocrinol.*, **56**, 523 (1955).

(8) H. S. Lipscomb and D. H. Nelson, *ibid.*, **71**, 13 (1962).

(9) C. H. Li, I. I. Geschwind, A. L. Levy, J. I. Harris, J. S. Dixon, N. G. Pon and J. O. Porath, *Nature*, **173**, 251 (1954).

(10) A. Tanaka, B. T. Pickering and C. H. Li, *Arch. Biochem. Biophys.*, **99**, 294 (1962).

renal adipose tissues of the rabbit. By the *in vivo* hypophysectomized frog assay,¹¹ the synthetic peptide had only one hundredth of the melanocyte-stimulating activity of the native hormones. Recent studies¹⁰ with various synthetic peptides related to ACTH appeared to show that the same amino acid sequence may be important for both lipolytic and melanocyte-stimulating activities. It is further noted that the decapeptide (α^{1-10} -ACTH) possesses approximately one tenth of the lipolytic¹⁰ and the melanocyte-stimulating¹² activities of the natural hormone whereas the pentapeptide¹³ (α^{15-19} -ACTH) has none. The synthetic pentadecapeptide described herein is the first instance where a separation of these two activities has been achieved. Moreover, as far as we are aware this report represents the first synthesis of a biologically active peptide in which the natural sequence of the ACTH structure has been altered.

N ^{α} -Carbobenzoxy-N^G-tosyl-L-arginine¹⁴ (I) was condensed with L-proline-*t*-butyl ester¹⁵ by N-ethyl-5-phenyl isoxazolium-3'-sulfonate¹⁶ (II) to give the crystalline protected dipeptide (III). III was hydrogenated and allowed to react with I, again with the aid of II. The protected tripeptide was converted to the pentapeptide N ^{α} -carbobenzoxy-N ^{ϵ} -*t*-butyloxycarbonyl-L-lysyl-N ^{ϵ} -*t*-butyloxycarbonyl-L-lysyl-N^G-tosyl-L-arginyl-N^G-tosyl-L-arginyl-L-proline-*t*-butyl ester (IV) by stepwise reaction of the tripeptide base with N ^{α} -carbobenzoxy-N ^{ϵ} -*t*-butyloxycarbonyl-L-lysine *p*-nitrophenyl ester.¹⁷ IV was purified by countercurrent distribution in the toluene system¹ ($K = 0.25$); m.p. 105–110°; $[\alpha]^{25}_D -36^\circ$ (*c* 1, methanol). *Anal.* Calcd.: C, 56.4; H, 7.22; N, 13.2; S, 4.64. Found: C, 56.2; H, 7.33; N, 13.0; S, 4.69.

IV was hydrogenated to yield the pentapeptide base (V) which was purified by countercurrent distribution in the toluene system¹ ($K = 0.73$); m.p. 112–117°; $[\alpha]^{25}_D -33.7^\circ$ (*c* 1, methanol). *Anal.* Calcd.: C, 54.8; H, 7.51; N, 14.6. Found: C, 54.5; H, 7.72; N, 14.4.

V was treated with crystalline carbobenzoxy-L-seryl-L-tyrosyl-L-seryl-L-methionyl- γ -benzyl-L-glutamyl-L-histidyl-L-phenylalanyl-N^G-tosyl-L-arginyl-L-tryptophyl-glycine⁵ in the presence of II to give the protected pentadecapeptide (VI). VI was purified by countercurrent distribution in the carbon tetrachloride system¹ followed by washing with methanol; m.p. 225–230° dec.; $[\alpha]^{25}_D -51.5^\circ$ (*c* 2.4, dimethylformamide). *Anal.* Calcd.: C, 57.0; H, 6.48; N, 14.0. Found: C, 56.6; H, 6.17; N, 13.8.

VI was treated with trifluoroacetic acid and then with sodium in liquid ammonia¹⁸ to remove all the protecting groups. The crude pentadecapeptide was desalted and purified by chromatography in a carboxymethyl cellulose¹⁹ column. The purified $\alpha^{(1-10)+(15-19)}$ -ACTH was found to be homogeneous in paper and polyacrylamide gel²⁰ electrophoresis. Amino acid analysis of an acid hydrolysate of the synthetic pentadecapeptide both by the chromatographic method of

(11) L. T. Hogben and D. Slome, *Proc. Roy. Soc. (London)*, **B108**, 10 (1931).

(12) B. T. Pickering and C. H. Li, *Biochem. Biophys. Acta*, **62**, 475 (1962).

(13) J. Meienhofer and C. H. Li, *J. Am. Chem. Soc.*, **84**, 2434 (1962).

(14) J. Ramachandran and C. H. Li, *J. Org. Chem.*, **27**, 4006 (1962).

(15) G. W. Anderson and F. M. Callahan, *J. Am. Chem. Soc.*, **82**, 3359 (1960).

(16) R. B. Woodward, R. A. Olofson and H. Mayer, *ibid.*, **83**, 1010 (1961).

(17) R. Schwyzler and W. Rittel, *Helv. Chim. Acta*, **44**, 159 (1961).

(18) V. du Vigneaud and O. K. Behrens, *J. Biol. Chem.*, **117**, 27 (1937).

(19) E. A. Peterson and H. A. Sober, *J. Am. Chem. Soc.*, **78**, 751 (1956).

(20) R. A. Reisfeld, U. J. Lewis and D. E. Williams, *Nature*, **195**, 281 (1962).

